Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function. by Dintwe, O, Day, C, Smit, E, Nemes, E, Gray, C, Tameris, M, Mcshane, H, Mahomed, H, Hanekom, W, Scriba, T

The role of clinical symptoms in the diagnosis of intrathoracic tuberculosis in young children by Mcshane, H, Tameris, M, Luabeya, K, Geldenhuys, H, Scriba, T, Hussey, G, Mahomed, H, Landry, B, Hanekom, W, Hatherill, M

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. by Tameris, M, Geldenhuys, H, Luabeya, A, Smit, E, Hughes, J, Vermaak, S, Hanekom, W, Hatherill, M, Mahomed, H, Mcshane, H, Scriba, T

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses by Tameris, M, Geldenhuys, H, Luabeya, A, Smit, E, Hughes, J, Vermaak, S, Hanekom, W, Hatherill, M, Mahomed, H, McShane, H, Scriba, T

Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals. by Schmidt, B, Tameris, M, Geldenhuys, H, Luabeya, A, Bunyasi, E, Hawkridge, T, McClain, J, Mahomed, H, Scriba, T, McShane, H, Hatherill, M

Elevated IgG responses in infants are associated with reduced prevalence of Mycobacterium tuberculosis infection by Logan, E, Luabeya, A, Mulenga, H, Mrdjen, D, Ontong, C, Cunningham, A, Tameris, M, McShane, H, Scriba, T, Horsnell, W, Hatherill, M

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination by Bunyasi, E, Luabeya, A, Tameris, M, Geldenhuys, H, Mulenga, H, Landry, B, Scriba, T, Schmidt, B, Hanekom, W, Mahomed, H, McShane, H, Hatherill, M

Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study by Andrews, J, Nemes, E, Tameris, M, Landry, B, Mahomed, H, McClain, J, Fletcher, H, Hanekom, W, Wood, R, McShane, H, Scriba, T, Hatherill, M

Risk of disease after isoniazid preventive therapy for mycobacterium tuberculosis exposure in young HIV uninfected children by Mcshane, H, Tameris, M, Luabeya, K, Geldenhuys, H, Scriba, T, Hussey, G, Mahomed, H, Landry, B, Hanekom, W, Hatherill, M, Toefey, A, Hughes, E, Van Schalkwyk, A

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. by Matsumiya, M, Harris, SA, Satti, I, Stockdale, L, Tanner, R, O'Shea, M, Tameris, M, Mahomed, H, Hatherill, M, Scriba, T, Hanekom, W, Mcshane, H, Fletcher, H

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response by Matsumiya, M, Harris, SA, Satti, I, Stockdale, L, Tanner, R, O'Shea, M, Tameris, M, Mahomed, H, Hatherill, M, Scriba, T, Hanekom, W, McShane, H, Fletcher, H

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. by Hawkridge, T, Scriba, T, Gelderbloem, S, Smit, E, Tameris, M, Moyo, S, Lang, T, Veldsman, A, Hatherill, M, Merwe, L, Fletcher, H, Mahomed, H, Hill, A, Hanekom, W, Hussey, G, Mcshane, H

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants by Satti, I, Wittenberg, RE, Li, S, Harris, SA, Tanner, R, Cizmeci, D, Jacobs, A, Williams, N, Mulenga, H, Fletcher, HA, Scriba, TJ, Tameris, M, Hatherill, M, McShane, H

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A by Harris, SA, Satti, I, Matsumiya, M, Stockdale, L, Chomka, A, Tanner, R, O'Shea, MK, Thomas, Z-R, Tameris, M, Mahomed, H, Scriba, TJ, Hanekom, WA, Fletcher, HA, McShane, H

Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin (BCG) for infants of HIV infected mothers: A phase 2 randomized controlled tr... by Nemes, E, Hesseling, A, Tameris, M, Mauff, K, Downing, K, Mulenga, H, Rose, P, van der Zalm, M, Mbaba, S, Van As, D, Hanekom, W, Walzl, G, Scriba, T, McShane, H, Hatherill, M

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. by Tameris, M, McShane, H, McClain, J, Landry, B, Lockhart, S, Luabeya, A, Geldenhuys, H, Shea, J, Hussey, G, van der Merwe, L, de Kock, M, Scriba, T, Walker, R, Hanekom, W, Hatherill, M, Mahomed, H

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG by Tameris, M, McShane, H, McClain, J, Landry, B, Lockhart, S, Luabeya, A, Geldenhuys, H, Shea, J, Hussey, G, Van Der Merwe, L, De Kock, M, Scriba, T, Walker, R, Hanekom, W, Hatherill, M, Mahomed, H

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. by Scriba, T, Tameris, M, Mansoor, N, Smit, E, van der Merwe, L, Isaacs, F, Keyser, A, Moyo, S, Brittain, N, Lawrie, A, Gelderbloem, S, Veldsman, A, Hatherill, M, Hawkridge, A, Hill, A, Hussey, G, Mahomed, H, Mcshane, H, Hanekom, W

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. by Scriba, T, Tameris, M, Mansoor, N, Smit, E, van der Merwe, L, Mauff, K, Hughes, E, Moyo, S, Brittain, N, Lawrie, A, Mulenga, H, de Kock, M, Gelderbloem, S, Veldsman, A, Hatherill, M, Geldenhuys, H, Hill, A, Hussey, G, Mahomed, H, Hanekom, W, Mcshane, H

Trajectories of interferon-gamma release assay results over two years in independent cohorts from China, South Africa, Tanzania, and the United States by Chen, C, Xue, H, Horsburgh, CR, Amour, M, Hatherill, M, Tameris, M, von Reyn, CF, Rees, C, Shen, Y, McShane, H, García-Basteiro, AL, Liu, D, Wang, Y, Nathavitharana, RR, Graviss, EA, Shao, Y, Liu, Q, Lu, W, Zhu, L, Martinez, L